NCT04657861View on ClinicalTrials.gov

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

August 20, 2024

Study Completion Date

August 20, 2027

Conditions
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Interventions
DRUG

APRIL CAR-T cells

Each subject receive APRIL CAR T-cells by intravenous infusion

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER